Pacira BioSciences
PCRX
Pacira BioSciences (PCRX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.73
- EPS estimate
- $0.65
- EPS surprise
- +12.95%
- Revenue surprise
- +0.70%
- Revenue
- $192.4M
- Revenue estimate
- $191.1M
- Reported
- Aug 4, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | $0.65 | $0.73 | +12.95% | $192.4M | SEC |
| Q1 2026 | Apr 30, 2026 | $0.55 | $0.60 | +9.57% | $177.4M | SEC |
| Q4 2025 | Feb 26, 2026 | $0.90 | $0.57 | −37.01% | $196.9M | SEC |
| Q3 2025 | Nov 6, 2025 | $0.68 | $0.70 | +3.32% | $179.5M | SEC |
| Q2 2025 | Aug 5, 2025 | $0.71 | $0.74 | +4.23% | $181.1M | SEC |
| Q1 2025 | May 8, 2025 | $0.60 | $0.62 | +3.94% | $168.9M | SEC |
| Q4 2024 | Feb 27, 2025 | $0.84 | $0.91 | +8.94% | $187.3M | SEC |
| Q3 2024 | Nov 6, 2024 | $0.70 | $0.79 | +12.14% | $168.6M | SEC |
| Q2 2024 | Jul 30, 2024 | $0.70 | $0.89 | +27.34% | $178.0M | SEC |
| Q1 2024 | May 7, 2024 | $0.62 | $0.62 | −0.02% | $167.1M | SEC |
| Q4 2023 | Feb 29, 2024 | $0.88 | $0.89 | +0.76% | $181.2M | SEC |
| Q3 2023 | Nov 2, 2023 | $0.78 | $0.72 | −7.78% | $163.9M | SEC |
| Q2 2023 | Aug 2, 2023 | $0.76 | $0.78 | +2.81% | $169.5M | SEC |
| Q1 2023 | May 3, 2023 | $0.62 | $0.53 | −14.10% | $160.3M | SEC |
| Q4 2022 | Feb 28, 2023 | $0.83 | $0.80 | −3.56% | $172.0M | SEC |
| Q3 2022 | Nov 3, 2022 | $0.77 | $0.64 | −16.51% | $167.5M | SEC |
| Q2 2022 | Aug 3, 2022 | $0.85 | $0.51 | −40.15% | $169.4M | SEC |
| Q1 2022 | May 4, 2022 | $0.83 | $0.64 | −23.06% | $158.0M | SEC |
| Q4 2021 | Feb 24, 2022 | $0.90 | $0.97 | +7.42% | $159.2M | SEC |
| Q3 2021 | Nov 3, 2021 | $0.65 | $0.72 | +10.77% | $127.7M | SEC |
Quarterly revenue
Frequently asked questions
When did Pacira BioSciences (PCRX) last report earnings?
Pacira BioSciences last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did PCRX beat earnings estimates?
Yes. Pacira BioSciences reported EPS of $0.73 for Q2 2026 against a $0.65 estimate — a 12.95% beat.
How much revenue did PCRX report last quarter?
Pacira BioSciences reported $192.4M in revenue for Q2 2026, against a consensus estimate of $191.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.